NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
RegulatorypositiveUbesloEvlarcoPositive
AI Analysis
Summary
NewAmsterdam Pharma and Menarini Group received a positive CHMP opinion recommending marketing authorization for Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib/ezetimibe fixed-dose combination) in Europe, supporting potential commercialization of both formulations.
Outcome Details
Positive CHMP opinion recommending marketing authorization for obicetrapib monotherapy and obicetrapib/ezetimibe fixed-dose combination
Importance:8/10
Sentiment:
0.85
CHMP opinionEuropean regulatorymarketing authorizationobicetrapibfixed-dose combination
Related Companies
Read the original article
Published by GlobeNewswire Pharma on July 24, 2026 12:00 PM